Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | GFER | P55789 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | STAT3 | P40763 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | DHODH | Q02127 | 1/20 | 0.57 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418857 | 0.89 | MEN1 (0.65) | MEN1KMT2AGFERCYP3A4STAT3 | |
| SCHEMBL420252 | 0.88 | HPGD (0.72) | MEN1KMT2AGFERCYP3A4STAT3 | |
| SCHEMBL29750310 | 0.86 | MEN1 (1.00) | MEN1KMT2AGFERCYP3A4STAT3 | |
| SCHEMBL6830501 | 0.85 | KMT2A (0.76) | MEN1KMT2AGFERCYP3A4STAT3 | |
| SCHEMBL18313926 | 0.85 | MEN1 (0.65) | MEN1KMT2AGFERCYP3A4STAT3 | |
| SCHEMBL6830407 | 0.82 | MEN1 (0.71) | MEN1KMT2AGFERCYP3A4STAT3 | |
| SCHEMBL418103 | 0.79 | SERPINE1 (0.71) | MAPTHTTKDM4ELMNASERPINE1 | |
| SCHEMBL29788462 | 0.79 | DHODH (0.80) | KMT2AMAPTHPGDKDM4ELMNA | |
| SCHEMBL2291034 | 0.79 | DHODH (0.80) | KMT2AMAPTHPGDKDM4ELMNA | |
| SCHEMBL24426075 | 0.78 | MEN1 (0.72) | MEN1KMT2AGFERCYP3A4STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| EP-2990057-B1 | PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT | RENASCIENCE CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-10092537-B2 | Use for PAI-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2018-10-09 | — | — | US | disclosed |
| US-20160158188-A1 | NOVEL USE FOR PAI-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-2990057-A1 | NOVEL USE FOR PAI-1 INHIBITOR | Renascience Co., Ltd. (JP) | 2016-03-02 | — | — | EP | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158188-A1 | NOVEL USE FOR PAI-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | MEN1 1229/4885KMT2A 3323/4885GFER 3112/4885 |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | MEN1 844/4885KMT2A 4433/4885GFER 2965/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | MEN1 844/4885KMT2A 4433/4885GFER 2965/4885 |
| US-10092537-B2 | Use for PAI-1 inhibitor | SERPINE1, SERPINC1, SERPINB1 | MEN1 1187/4885KMT2A 3437/4885GFER 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.